Abstract
Background Cervical cancer continues to be a major health issue in low- and middle-income countries (LMICs). Despite increasing access to screening, access to precancer treatment remains a significant challenge in LMICs, highlighting a need for innovative, accessible, and resource-appropriate treatment approaches, including self-administered therapies.
Methods A cross-sectional mixed-methods study was conducted among men aged 25-65 with a current female partner in Kisumu County, Kenya. Participants were sequentially recruited and surveyed to evaluate their understanding of HPV and cervical cancer, their views on screening and treatment, and their attitudes toward self-administered therapies. Focus group discussions with a subset of the survey participants further explored their treatment preferences and perceptions.
Results Two hundred fourteen men participated in the survey, and 39 men participated in focus group discussions. The median age was 39 years, and 51% had a primary school education or less. Most (96%) were in a committed relationship, and 74% earned $10 or less daily. There was strong support for self-administered topical therapies, with 98% willing to support their partners using such treatments if available. Additionally, most participants were open to supporting necessary abstinence or condom use, though 76% believed their partners might hesitate to request condom use. When given an option, most preferred their partner to self-administer such therapies at home compared to provider administration at a health facility, citing convenience, cost-effectiveness, and privacy. Preferences varied between two potential therapies, 5-Fluorouracil (5FU) and Artesunate, based on their administration frequency, duration, and abstinence requirements. Qualitative findings largely supported the quantitative analysis.
Conclusions The study demonstrates strong support for self-administered topical therapies for cervical precancer among Kenyan men. Additional research on acceptability, feasibility, and efficacy in different LMICs could pave the way for these therapies to help bridge current cervical precancer treatment gaps in these settings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under Award Number K12HD103085 and the Victorias Secret Global Fund for Womens Cancers Career Development Award, in Partnership with Pelotonia Foundation and the American Association of Cancer Research (AACR). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The study funders had no role in the research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the ethics review boards at Maseno University School of Medicine in Kenya and the University of North Carolina at Chapel Hill in the US. All participants provided consent prior to participation in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email addresses: CM: chemtai_mungo{at}med.unc.edu, tel: +1 919 966 5280
KA: kadewumi{at}email.unc.edu, tel: +1 951 520 7150
GE: gkellis{at}email.unc.edu, tel: +1 240 246 6061
MR: mercyrop42{at}gmail.com, tel: +254 710 137213
EA: everlynadoyo{at}gmail.com, tel: +254 711 590808
YZ: yating{at}live.unc.edu, tel: +1 984 291 3869
LR: lisa_rahangdale{at}med.unc.edu, tel: +1 919 381 2464
Data Availability
All data produced in the present study are available upon reasonable request to the authors
List of Abbreviations
- LMIC
- low- and middle-income countries
- 5FU
- 5-Fluorouracil
- HPV
- human papillomavirus
- HIV
- human immunodeficiency virus
- WHO
- World Health Organization
- FGD
- focus group discussion